The Form 4 filing, which reports an insider's stock trades to the SEC, was filed on November 12, 2026. It covers sales from November 9 through November 10, 2026.
The filing identifies James M. Frates as chief financial officer of Amylyx Pharmaceuticals (AMLX). It lists four sale transactions for him.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-09 |
| Date of Latest Transaction | 2026-11-10 |
| Buy/Sell | sell |
| Transaction Count | 4 |
| Shares Transacted | 40,000 |
| Price | $30.19 |
| Total Transaction Value | $1,207,742.22 |
| Insider | |
| Ticker Symbol | AMLX |
| Company | Amylyx Pharmaceuticals, Inc. |
| Insider Name | FRATES JAMES M |
| Insider Title | Chief Financial Officer |
| Sector - Industry | Healthcare - Drug Manufacturers - Specialty & Generic |
| Holdings | |
| Total Shares Owned After Transaction | 233,625 |
| Position Size Change | 14.62% |
| Filing | |
| Filing Date | 2026-11-12 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were sales of company shares, listed under transaction code S. James M. Frates sold 40,000 shares across four transactions.
What was the average price of the transaction?
The average sale price was $30.19 per share, rounded to the nearest cent.
How did this transaction affect the insider's holdings?
James M. Frates reported owning 233,625 shares after selling 40,000 shares. The shares sold made up 14.62% of the shares he held before the sales.
What's the total transaction value?
The total value of the four sales was $1,207,742.22.
Are there any special circumstances around this transaction?
The transaction information includes a Rule 10b5-1 trading-plan reference. These plans set trading instructions in advance. The available details leave unclear which of the four sales the reference covers. Footnote text and plan terms were unavailable for this report. The plan's start date and trading schedule remain unknown.
For research purposes only; not investment advice.